CTOs on the Move

Marathon Kids

www.marathonkids.org

 
Marathon Kids is a nonprofit organization, headquartered in Austin, TX, that is dedicated to improving the health of children by providing them with the motivation, tools and support to live happier, healthier lifestyles. Marathon Kids started out with the simple mission to introduce children to the joy of running, but it has evolved into the only evidence-based running/walking program for elementary-school kids in the United States. We`ve stood up to rigorous tests to prove that our program mitigates the negative health effects of a sedentary lifestyle and ardently pushes for access around the country. The vast majority of kids don`t ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.marathonkids.org
  • 4544 South Lamar Blvd. Bldg 300 Suite 350
    Austin, TX USA 78745
  • Phone: 512.477.1259

Executives

Name Title Contact Details
Anne-Marie Tucker
 Chief Technology Officer Profile

Similar Companies

E.I. Medical

E.I. Medical is a Loveland, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ozone House-one

Ozone House-one is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cook Children's Medical Center - Cook Children's Community Clinics

Cook Children's Medical Center - Cook Children's Community Clinics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Management Services On-Call

Management Services On-Call is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.